Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02055742 · ClinicalTrials.gov registry record
Detection of Chlamydia (CT) and Gonorrhea (NG)
A clinical trial, sponsored by Meridian Bioscience.
- Completed
- Registry status
- 700
- Enrollment target
NCT02055742: Completed study, sponsored by Meridian Bioscience.
NCT02055742 is a clinical trial that has completed, run by Meridian Bioscience. The registered enrollment target is 700 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02055742 has completed, sponsored by Meridian Bioscience.
- COMPLETED
- Registry status
- 700 participants
- Enrollment target
Study Summary
To evaluate the illumigene Chlamydia and illumigene Gonorrhea assays, using the illumipro-10, with male urine, female urine, physician-collected (medical professional) endocervical swabs and self-collected vaginal swabs taken from symptomatic and asymptomatic patient populations.
Primary Outcome
Testing of each set of subject samples is completed within 60 days of sample collection
Interventions
- DEVICE illumigene CT and NG assays, illumipro-10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2014-03-01 |
| Est. Completion | 2014-09-09 |
What the finished NCT02055742 record still lists
NCT02055742 is an observational study that tracks outcomes without assigning an intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which illumigene CT and NG assays, illumipro-10 is the first listed.
NCT02055742 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02055742 about?
NCT02055742 is a clinical study titled "Detection of Chlamydia (CT) and Gonorrhea (NG)". To evaluate the illumigene Chlamydia and illumigene Gonorrhea assays, using the illumipro-10, with male urine, female urine, physician-collected (medical professional) endocervical swabs and self-collected vaginal swabs taken from symptomatic and asymptomatic patient populations.
What is the current status of trial NCT02055742?
This trial is currently completed. The enrollment target is 700 participants. The study started on 2014-03-01. Estimated completion is 2014-09-09.
What interventions are being tested in trial NCT02055742?
The interventions under investigation include: illumigene CT and NG assays, illumipro-10 (DEVICE).
Who is sponsoring clinical trial NCT02055742?
This trial is sponsored by Meridian Bioscience, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI